P268 Ocular manifestations in a tertiary IBD centre: Better to keep an eye on. (16th January 2018)

• Record Type: Journal Article
• Authors: Rizzatti, G; Gerardi, S; Manganelli, C; Petito, V; Graziani, C; Holleran, G; Lopetuso, L R; Schiavoni, E; Napolitano, D; Pizzoferrato, M; Laterza, L; Ianiro, G; Caporossi, A; Papa, A; Armuzzi, A; Gasbarrini, A; Scaldaferri, F
• Is Part Of: Journal of Crohn's and colitis. Volume 12:Number 1(2018:Jan.)Supplement 1
• Page Start: S236
• Page End: S236
• Publication Date: 2018-01-16
• Subjects: Inflammatory bowel diseases -- Periodicals; 616.344005
• DOI: 10.1093/ecco-jcc/jjx180.395
• Languages: English
• ISSNs: 1873-9946

Abstract

Abstract: Background: Extra-intestinal manifestations (EIM) are common in inflammatory bowel disease (IBD) occurring in up to 50% of the cases 1, being ocular manifestations described to be 0.3% to 13.0% of the cases 2. Reported data, however, mostly rely on not recent population based studies. In fact, the few available prospective studies, suggest a much higher occurrence of ocular diseases, ranging from 29% 3 to 71% 4. Aim of the study was to assess the prevalence of ocular disease in a cohort of IBD patients followed in tertiary referral Italian centre. Methods: IBD patients followed at our centre were consecutively enrolled in the study. Enrolled patients underwent ocular evaluation including assessment of visual acuity, examination of fundus oculi and anterior ocular segment as well as measure of intraocular pressure, Schirmer's test and break up time test, when appropriated. Results: A total of 193 IBD patients were enrolled in the study, 54.9% females and 45.1% males, 47.7% CD, 43.5% UC, and 8.8% indeterminate colitis, 35.7% of patients had a moderate–severe activity of disease, 39.4% were under active steroid therapy, 35.8% were under anti-TNFalpha and 64.3% were taking mesalamine. Overall, any ocular disease was identified in 46.1% of enrolled patients, 17.1% CD and 23.8% UC and 5.2% IC. The most common ocular disease was dry eye (12.4%). At multivariate analysis use of mesalamine (OR 2.3, 95% CI 1.1–5.0), steroids (OR 3.6, 95% CI 1.1–11.8) and moderate–severe activity of disease (OR 5.1, 95% CI 2.3–11.1) were all correlated with an increased risk of ocular disease. Conclusions: Ocular manifestations in IBD patients are more frequent than reported especially in referral centre. Patients under treatment with mesalamine or steroids and with a moderate–severe disease activity might benefit of an ophthalmological evaluation.